臨床研究等提出・公開システム

Skeletal muscle-derived cell implantation for the treatment of fecal incontinence: a phase III, randomized, controlled, double blind, two-armed clinical study. (FI-3)

Phase III clinical study of ICEF15 in patients with urge fecal incontinence

Sachiya Ikeda

Innovacell K.K.

MEGURO VILLA GARDEN 5F, 3-5-11 Kamiosaki, Shinagawa-ku, Tokyo

sachiya.ikeda@innovacell.co.jp

Takashi Kiriyama

Innovacell K.K.

MEGURO VILLA GARDEN 5F, 3-5-11 Kamiosaki, Shinagawa-ku, Tokyo

+81-3-6555-4437

takashi.kiriyama@innovacell.co.jp

Recruiting

Oct. 31, 2022

Interventional

randomized controlled trial

double blind

placebo control

parallel assignment

treatment purpose

1. Patients must be at least 18 years old and over
2. Patients who are mentally competent and able to understand all study requirements
3. Female patients of childbearing potential willing to use appropriate methods of contraception
4. Patient has symptoms of urge fecal incontinence with a disease duration of at least 6 months and did not improve sufficiently by conservative treatment performed for at least 3 months
5. Urge fecal incontinence episodes that occur more than twice a week
6. Incremental voluntary maximum squeeze pressure on anal manometry is 100mmHg or less in women and 150mmHg or less in men
7. Ultrasound of the anal canal showing the overall extent of external anal sphincter injury and tear of 180 degrees or less

1. Patients for whom the investigator determines that FI has a different cause than external anal sphincter dysfunction.
2. Patients with global fragmentation of the external anal sphincter as assessed by anal canal ultrasound
3. Patients who underwent any anorectal surgery within 6 months before screening visit
4. Patients who underwent a total of two or more external anal sphincter-related surgeries
5. Patients who currently have anal fistulas or fissures or have recurrent anal fistulas or fissures
6. Patients with poorly controlled chronic constipation including obstructed defecation syndrome
7. Patients with indications against a surgery under anesthesia
8. Patients with a malignant disease not in remission for 5 years or more
9. Patients who have undergone radiation therapy of the bowel and pelvis
10. Patients who have undergone chemotherapy within last 5 years prior to study enrolment and/or chemotherapy related neuropathy of the bowel and pelvis
11. Patients with compromised immune system and/or rheumatic disease, and patients under immunosuppressive therapy
12. Patients with a diagnosis of chronic inflammatory bowel disease
13. Patients suffering from a disease which has not been resolved within 4 weeks prior to screening including fever and/or diarrhea of unknown reasons (4 weeks)
14. Patients diagnosed with human immunodeficiency virus (HIV), acute or chronic viral hepatitis HCV, acute or chronic viral hepatitis HBV, active Syphilis or HTLV (tested upon risk assessment by investigator)
15. Patients diagnosed with any kind of skeletal muscle disease and/or neuronal disorders
16. Patients with severe myocardial disorders, irregular pulse or a pacemaker
17. Patients with implantations of metal components in the electrical stimulation treatment area
18. Patients with uncontrolled diabetes mellitus type I or II, or suffering from diabetic peripheral neuropathic pain
19. Patients with clinically relevant abnormal laboratory values judged by the responsible investigator as relevant for the study treatment

Both

Fecal Incontinence

A) Cell tissue procurement of skeletal muscle tissue from musculus pectoralis major
B) Performance of pelvic floor electrical stimulation before and after implantation of ICEF15
C) Implantation of ICEF15 into external anal sphincter

Changes in frequency of urge fecal incontinence episodes [ Time Frame: 12 Months ]

+81-436-62-1211

Dec. 20, 2022

No

Austria/Bulgaria/Czechia/France/Italy/Poland/Spain/Sweden/United Kingdam